A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

NCT05819866 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Adrenoleukodystrophy (cALD)

Interventions

DRUG: Leriglitazone
DRUG: Placebo

Sponsor

Minoryx Therapeutics, S.L.